US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
pharma · Non Small Cell Lung Cancer · Locally Advanced Solid Tumor · TNGX
Tango Therapeutics
Tango Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Boston, USA HQ
2017 Founded
154 Employees
Public company Type
TNGX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2017
- Employees
- 154
- Programs
- 7
- Drugs
- 2
- Patents
- 9
Tango Therapeutics pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Tango Therapeutics drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator